Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Kiora is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases, including inherited retinal degenerations and inflammatory retinal conditions.
Through this page, users can review Kiora’s periodic and current reports, such as Forms 10-K, 10-Q, and 8-K. Recent Form 8-K filings dated August 8, 2025, and November 7, 2025, reference press releases announcing quarterly financial results and updates on clinical development progress for the company’s Phase 2 trials, ABACUS-2 for KIO-301 and KLARITY for KIO-104. These filings help investors understand how Kiora reports research and development expenses, collaboration revenue and credits, and other items affecting its financial position.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers interpret complex sections of Kiora’s annual reports (Form 10-K) and quarterly reports (Form 10-Q). Users can quickly see how the company describes its retinal disease pipeline, risk factors, collaboration agreements with partners such as Théa Open Innovation and Senju Pharmaceutical, and other material information.
In addition to earnings-related filings, this page can surface other SEC documents relevant to KPRX shareholders, including registration statements and, when applicable, insider transaction reports on Form 4. Real-time updates from the EDGAR system ensure that new Kiora filings appear promptly, while AI-generated overviews provide context so investors can focus on how developments in KIO-301, KIO-104, and related partnerships may affect the company’s overall profile.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.
Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA will resign effective April 17, 2026 to pursue another opportunity. The company stated his departure is not due to any disagreement over operations, policies, or practices and has begun a search for his successor.
Kiora emphasized continued progress in its retinal disease pipeline. In the ABACUS-2 Phase 2 trial of KIO-301, a planned safety review allowed enrollment of remaining patients in the 50µg dose cohort and cleared initiation of the 100µg cohort. In the KLARITY Phase 2 trial of KIO-104, all planned safety checkpoints have been cleared and patient enrollment is ongoing.
Kiora Pharmaceuticals reported a net loss of $10.8 million for 2025, compared with net income of $3.6 million in 2024, mainly because 2024 included $16.0 million of collaboration revenue and 2025 recorded a $4.6 million in-process R&D impairment related to KIO-104.
Revenue was zero in 2025, while operating expenses rose as R&D increased to $10.8 million with two Phase 2 trials underway and G&A reached $5.7 million. Kiora ended 2025 with $17.1 million in cash, cash equivalents and short-term investments plus $3.5 million in receivables and projects its cash runway into late 2027.
Pipeline progress included advancing KIO-301 and KIO-104 into active Phase 2 studies in retinal diseases and signing an option agreement with Senju Pharmaceutical with potential value of up to $110 million plus royalties, alongside continued work on the KIO-300 ion-channel modulator platform.
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on therapies for retinal diseases. Its lead candidate, KIO-301, is a small-molecule “photoswitch” being developed for late-stage retinitis pigmentosa and other inherited retinal dystrophies. A Phase 1b trial showed safety and vision-related improvements, and a 36‑patient Phase 2 ABACUS‑2 trial in RP is enrolling under a global co-development agreement with Théa Open Innovation, which funds all KIO‑301 R&D.
The company is also advancing KIO-104, an intravitreal DHODH inhibitor for retinal inflammation such as diabetic macular edema and posterior non‑infectious uveitis, with a Phase 2 KLARITY trial dosing patients. A topical DHODH inhibitor, KIO‑101, is being positioned for partnering in ocular manifestations of autoimmune diseases. Kiora reported a $10.8 million net loss for the year ended December 31, 2025, versus net income of $3.6 million in 2024, and held $17.1 million in cash and short-term investments, which it expects to fund operations into late 2027. As of March 21, 2026, there were 3,950,628 shares of common stock outstanding.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a small tax-related share disposition. On March 3, 2026, he transferred 238 shares of common stock at $2.02 per share to satisfy tax withholding obligations. After this transaction, he directly held 26,137 common shares.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related stock transaction. On March 3, 2026, he disposed of 238 shares of common stock at $2.02 per share as a tax-withholding disposition, a method of paying tax obligations using shares. After this transaction, he directly owned 45,865 common shares.
Kiora Pharmaceuticals Inc. received an amended Schedule 13G from Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon reporting beneficial ownership tied to warrants for up to 464,676 common shares, or 9.9% of the company based on 3,677,935 shares outstanding as of November 5, 2025. These shares are issuable upon exercise of warrants that include a 9.99% beneficial ownership blocker, so as of the December 31, 2025 event date the reporting persons state they could not exercise the warrants. The filers characterize the position as held in the ordinary course of business and state it is not for the purpose of changing or influencing control.
Kiora Pharmaceuticals (KPRX) received an amended Schedule 13G from Nantahala Capital Management and affiliates reporting beneficial ownership of 9.99% of the common stock as of September 30, 2025. The group reports 363,712 shares beneficially owned, which includes 207,285 shares that may be acquired within sixty days through the exercise of warrants.
The reporting persons disclose 0 shares with sole voting or dispositive power and 363,712 shares with shared voting and dispositive power. The filing is certified as securities held in the ordinary course and not for the purpose of changing or influencing control.